Copenhagen N, Capital Region, DK
New Startup (0-1M TTM Revenue)
BioPhenyx helps our customers determine drug targets and drug responses in a multitude of settings from the earliest target discovery to patient response to therapeutics. Exceptional data on the role of molecular targets in disease etiology and their responsiveness to drug candidates are critical for better development of therapeutics. This will reduce attrition rates in development programs and clinical trials.
The BioPhenyx team has invented and developed the CRISPR-Select technology to generate unmatched data quality. CRISPR-Select in Nature Genetics: https://www.nature.com/articles/s41588-022-01224-7. CRISPR-Select as Resarch Highlight in Nature Biotechnology: https://www.nature.com/articles/s41587-022-01647-x.
We perform precise, fast (weeks), and quantitative analysis of a candidate drug target or a drug response in cells, where we introduce mutation(s) needed to address the question. This is done with no need for cell line generation and clonal selection.
We may help to answer the following questions, and more:
Is my protein or gene a good drug target?
Is my drug candidate working?
Does my drug act on-target?
Which patient genotypes will respond to my drug?
How should my drug best block my target:
- Catalytic inhibition?
- Protein-protein interaction inhibition?
- Elimination of protein expression?
Is my mutation benign or pathogenic?
|BioPhenyx Ole Maaløes Vej 3 Copenhagen N, Capital Region, 2200 Denmark|
To request access, simply fill out the form below and we will contact you.